Mode
Text Size
Log in / Sign up
N/A Completed N=115 Randomized Double-blind Treatment

Efficacy of the Quell Wearable Device for Chronic Overlapping Pain Conditions

Postoperative Pain · Adults 21 and Older · Multiple Chronic Overlapping Pain Conditions · Hypersensitivity
Source: ClinicalTrials.gov NCT05540002 ↗
Enrolled (actual)
115
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcomePrimary: The Brief Pain Inventory Interference Scale (BPI) — 5.7; 5.7 score on a scale

Summary

This study will examine the pain-relieving effects of a transcutaneous electrical nerve stimulator device called a Quell for persons with multiple chronic overlapping pain conditions.

Outcome Measures

OutcomeResultp-value
PRIMARY
The Brief Pain Inventory Interference Scale (BPI)
5.7; 5.7
SECONDARY
Pain Catastrophizing Scale (PCS)
25.0; 24.8
SECONDARY
Pain Disability Index (PDI)
38.3; 36.3
SECONDARY
Hospital Anxiety and Depression Scale (HADS)
19.1; 16.9
SECONDARY
Pain Detect Neuropathic Pain Questionnaire (painDETECT)
16.1; 16.5
SECONDARY
Symptom Impact Questionnaire (SIQR)
115.8; 106.1
SECONDARY
Patient's Global Impression of Change (PGIC)
4.2; 4.0
SECONDARY
Healthcare Utilization
1.3; 1.6; 0.0; 0.1
SECONDARY
Satisfaction and Qualitative Questions
7.6; 7.4
SECONDARY
Quantitative Sensory Testing (QST)
0.6; 0.0
SECONDARY
The Brief Pain Inventory Pain Intensity Scale (BPI)
-0.5; -1.0
SECONDARY
MasterMyPain App
3.9; 5.1

Eligibility Criteria

Inclusion Criteria

  • Ages 21 and older
  • Pain duration > 3 months
  • Diagnosed by physician with multiple chronic pain conditions
  • Have chronic pain related to multiple chronic pain diagnoses (headaches, joint pain, back pain, or any of the other COPCs)
  • Average 4 or greater on pain intensity scale of 0 to 10
  • Pain is not accounted for by any other progressive disease (e.g., cancer, MS)
  • Meets sensory hypersensitivity cutoffs based on QST-assessed evidence
  • Own a smartphone (iPhone or Android device) and can download the pain app (MasterMyPain) and the Quell Relief mobile app onto their device
  • Able to speak and understand English

Exclusion Criteria

  • Diagnosis of cancer or any other malignant disease
  • Acute osteomyelitis or acute bone disease
  • Present of past DSM-V diagnosis of schizophrenia, delusional disorder, psychotic disorder, or dissociative disorder that would be judged to interfere with study participation
  • Pregnancy
  • Any clinically unstable systemic illness judged to interfere with treatment
  • A pain condition requiring urgent surgery
  • An active substance use disorder, such as cocaine or IV heroin use that would interfere with study participation
  • Have an implanted cardiac pacemaker, defibrillator, or other implanted device.
  • Reynaud's syndrome
  • Open cuts/sores
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05540002). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search